Patents by Inventor Sang W. Tam
Sang W. Tam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090306027Abstract: The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.Type: ApplicationFiled: April 4, 2007Publication date: December 10, 2009Applicants: NitoMed, Inc., Unversity of Pittsburgh of the Commonwealth System of the Higher EducationInventors: Manuel Worcel, Michael Sabolinski, Sang W. Tam, Dennis M. McNamara
-
Publication number: 20090253662Abstract: The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (Ic) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a ?344 (T/T) polymorphism or a ?344 (C/C) polymorphism in an aldosterone synthase CYP11B2 gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceuticallyType: ApplicationFiled: October 4, 2006Publication date: October 8, 2009Applicants: NitroMed, Inc., University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Manuel Worcel, Michael Sabolinski, Sang W. Tam, Dennis M. McNamara
-
Publication number: 20090192128Abstract: The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceuticallyType: ApplicationFiled: October 4, 2006Publication date: July 30, 2009Applicants: NitroMed Inc., University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Manuel Worcel, Michael L. Sabolinski, Sang W. Tam, Dennis M. McNamara
-
Patent number: 7432285Abstract: The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent.Type: GrantFiled: November 15, 2006Date of Patent: October 7, 2008Assignee: NitroMed, Inc.Inventors: Ramani R. Bandarage, Upul K. Bandarage, Xinqin Fang, David S. Garvey, L. Gordon Letts, Joseph D. Schroeder, Sang W. Tam
-
Patent number: 5480892Abstract: There are described novel (N-phthalimidoalkyl) piperidine compounds which exhibit selective sigma-receptor antagonism and therefore are useful in the treatment of physiological or drug induced psychosis and dyskinesia in a mammal. Also described are pharmaceutical compositions containing sigma selective compounds and methods of using these compositions for treating physiological or drug induced psychosis or dyskinesia in a mammal. Further provided are methods for preparing the compounds of this invention.Type: GrantFiled: August 31, 1994Date of Patent: January 2, 1996Assignee: The Du Pont Merck Pharmaceutical CompanyInventors: Engelbert Ciganek, Sang W. Tam, Ann S. Wright
-
Patent number: 5356906Abstract: There is described novel (N-phthalimidoalkyl) piperidine compounds which exhibit selective sigma-receptor antagonism and therefore are useful in the treatment of physiological or drug induced psychosis and dyskinesia in a mammal. Also described are pharmaceutical compositions containing sigma selective compounds and methods of using these compositions for treating physiological or drug induced psychosis or dyskinesia in a mammal. Further provided are methods for preparing the compounds of this invention.Type: GrantFiled: April 30, 1992Date of Patent: October 18, 1994Assignee: The Du Pont Merck Pharmaceutical CompanyInventors: Engelbert Ciganek, Sang W. Tam, Ann S. Wright
-
Patent number: 5317024Abstract: Novel unsaturated ether derivatives of alkyl piperidine and pyrrolidine compounds, pharmaceutical compositions containing them, methods of preparation and methods of using these compounds as antipsychotic agents are disclosed.Type: GrantFiled: August 3, 1993Date of Patent: May 31, 1994Assignee: DuPont Merck Pharmaceutical Co.Inventors: Gary A. Cain, Thomas E. Christos, Sang W. Tam
-
Patent number: 5296479Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.Type: GrantFiled: February 6, 1992Date of Patent: March 22, 1994Assignee: The Du Pont Merck Pharmaceutical CompanyInventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
-
Patent number: 5278045Abstract: This invention is directed to a composition comprising a substantially purified protein which enhances endogenous stimulus-induced neurotransmitter release, said neurotransmitter being selected from the group consisting of acetylcholine, dopamine or serotonin, said protein having a binding affinity constant of at least 2.9.+-.0.8 nM for tritiated 3,3-bis(4-pyridinylmethyl)-1-phenylindolin-2-one as determined by a Scatchard analysis, and said protein being trypsin sensitive and phospholipase C insensitive.Type: GrantFiled: February 28, 1990Date of Patent: January 11, 1994Assignee: Du Pont Merck Pharmaceutical CompanyInventor: Sang W. Tam
-
Patent number: 5266572Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.Type: GrantFiled: June 18, 1992Date of Patent: November 30, 1993Assignee: The Du Pont Merck Pharmaceutical CompanyInventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
-
Patent number: 5252586Abstract: Novel unsaturated ether derivatives of alkyl piperidine and pyrrolidine compounds, pharmaceutical compositions containing them, methods of preparation and methods of using these compounds as antipsychotic agents are disclosed.Type: GrantFiled: September 28, 1990Date of Patent: October 12, 1993Assignee: The Du Pont Merck Pharmaceutical CompanyInventors: Gary A. Cain, Thomas E. Christos, Sang W. Tam
-
Patent number: 5243048Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.Type: GrantFiled: February 6, 1992Date of Patent: September 7, 1993Assignee: The Du Pont Merck Pharmaceutical CompanyInventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
-
Patent number: 5169855Abstract: There are provided piperidine ether derivatives, pharmaceutical and agricultural compositions containing them useful for treating physiological or drug induced psychosis or dyskinesia in a mammal or fungal disease in plants. Also provided are methods for preparing these compounds.Type: GrantFiled: March 28, 1990Date of Patent: December 8, 1992Assignee: Du Pont Merck Pharmaceutical CompanyInventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
-
Patent number: 5116846Abstract: There are provided N-aralkyl piperidine derivatives which are selective sigma receptor antagonists. These compounds and pharmaceutical compositions containing them are useful for treating physiological or drug induced psychosis or dyskinesia in a mammal.Type: GrantFiled: March 28, 1990Date of Patent: May 26, 1992Assignee: Du Pont Merck Pharmaceutical CompanyInventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
-
Patent number: 5109002Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.Type: GrantFiled: August 20, 1990Date of Patent: April 28, 1992Assignee: Du Pont Merck Pharmaceutical CompanyInventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam